Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Ide-cel induced responses in a majority of heavily pretreated patients with refractory and relapsed myeloma; MRD-negative status was achieved in 26% of treated patients. Almost ...
Publications
2 shownAnti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
We report the initial toxicity profile of a BCMA-directed cellular immunotherapy for patients with relapsed or refractory multiple myeloma. Antitumor activity was documented. (F...
Frequent Co-Authors
Researcher Info
- h-index
- 2
- Publications
- 2
- Citations
- 3,778
- Institution
- Hackensack University Medical Center
External Links
Identifiers
- ORCID
- 0000-0002-3604-2574
Impact Metrics
h-index
2
h-index: Number of publications with at least h citations each.